[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-365532-105":59,"doc-detail-365532-en":135},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":128,"head_meta":130,"extra_data":132,"updated_unix":134},105,"en","the-potential-of-secretogranin-v-as-a-prognostic-biomarker-in-non-small-cell-lung-cancer-a-scientific-study","The potential of secretogranin V as a prognostic biomarker in non-small cell lung cancer - A scientific study","","Secretogranin V (SCG5) is reported as aberrantly expressed across multiple cancers, with a hypothesized link to tumor progression and patient outcomes. This study evaluates SCG5 as a prognostic biomarker for non-small cell lung cancer (NSCLC) using bioinformatics, Western blotting, and immunofluorescence. TCGA and GEO pan-cancer analyses show consistent SCG5 upregulation and higher NSCLC tumor expression, where high SCG5 associates with poorer overall survival. COX regression confirms independent prognostic value, and immune infiltration patterns further support adverse outcome relevance through experimental validation in tissues and cell lines.",{"@graph":69,"@context":127},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/the-potential-of-secretogranin-v-as-a-prognostic-biomarker-in-non-small-cell-lung-cancer-a-scientific-study/365532/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/the-potential-of-secretogranin-v-as-a-prognostic-biomarker-in-non-small-cell-lung-cancer-a-scientific-study/365532.png","ImageObject",300,407,{"name":92,"@type":93},"WPS_1786070896","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-03","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",11,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119,123],{"name":110,"@type":111,"acceptedAnswer":112},"What is the main objective of the study on SCG5 in NSCLC?","Question",{"text":113,"@type":114},"To evaluate whether Secretogranin V (SCG5) can serve as a prognostic biomarker for non-small cell lung cancer by linking its expression to clinical outcomes and tumor biology.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How was SCG5 expression assessed in this research?",{"text":118,"@type":114},"The study used bioinformatics analysis of TCGA and GEO pan-cancer datasets, and validated elevated SCG5 levels in NSCLC tissues and cell lines with Western blotting and immunofluorescence.",{"name":120,"@type":111,"acceptedAnswer":121},"What prognostic relationship was found between SCG5 expression and patient survival?",{"text":122,"@type":114},"Patients with higher SCG5 expression showed lower overall survival, and univariate and multivariate COX regression supported SCG5 as an independent prognostic factor for NSCLC.",{"name":124,"@type":111,"acceptedAnswer":125},"How does SCG5 relate to the immune microenvironment?",{"text":126,"@type":114},"Immune infiltration analysis indicated a significant correlation between SCG5 expression and multiple immune cell subpopulations, suggesting SCG5’s potential role in adverse outcomes.","https://schema.org",{"og:url":83,"og:type":129,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":131,"canonical":83},"index,follow",{"doc_id":133,"site_id":62},365532,1790211036,{"code":4,"msg":5,"data":136},{"doc_id":133,"user_id":137,"nickname":92,"user_avatar":138,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":139,"file_id":140,"file_url":141,"file_type":142,"file_size":143,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":144,"language":145,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":146,"faqs":147,"seo_title":148,"seo_description":67,"update_tm":149,"read_time":150,"preview_page_count":19,"preview_urls":151},549768072016,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","[www. nature.com/scientificreports](www. nature.com/scientificreports)  \nOPEN  \nThe potential of secretograninVas a prognostic biomarker in nonsmall cell lung cancer  \nWeisong Zhang1,2,5, Rui Wang1,2,5, Rongqi Guo1,2,5, Yihao Wang1,2, Hao Wang1,2, Yangyang Li1,2, Xia Li3􀀍 & Jianxiang Song1,4􀀍  \nRecent studies indicate that SecretograninV (SCG5) is aberrantly expressed in various cancers and may be linked to tumor progression and prognosis. This study aims to evaluate the potential of SCG5 as a prognostic biomarker for non-small cell lung cancer (NSCLC). We employed a combination of bioinformatics analysis, Western blotting, and immunofluorescence techniques to investigate the role of SCG5 in NSCLC. A comprehensive analysis of TCGA and GEO pan-cancer datasets revealed a consistent upregulation of SCG5 across multiple cancer types. In NSCLC, SCG5 expression was significantly higher in tumor tissues compared to normal lung tissues (p \u003C 0.001) . Kaplan-Meier survival analysis demonstrated that patients with elevated SCG5 expression exhibited lower overall survival rates, suggesting a strong association with poor prognosis. Univariate and multivariate COX regression analyses, conducted on both TCGA cases and our collected patient data, confirmed SCG5 as an independent prognostic factor for NSCLC. Furthermore, immune infiltration analysis indicated a significant correlation between SCG5 expression and various immune cell subpopulations, underscoring its potential role as a biomarker for adverse outcomes. Western blot analysis further validated the elevated levels of SCG5 in NSCLC tissues and cell lines compared to their normal counterparts. Based on our findings, we hypothesize that SCG5 may serve as a valuable biomarker for predicting the prognosis of non-small cell lung cancer, thereby guiding future research in the fields of diagnosis, progression, therapy, and prognosis of NSCLC.  \nKeywords SCG5, Non-small cell lung Cancer, Biomarker, Prognosis, Bioinformatics analysis  \nLung cancer is the most common form of cancer and the leading cause of cancer death, accounting for 18.0% of all cancer deaths1. The prognosis for lung cancer is extremely poor, with a five-year survival rate of only 10–20% of patients diagnosed with lung cancer in most countries2. Non-small cell lung cancer is a highly heterogeneous tumor that accounts for approximately 85% of all newly diagnosed lung cancers3. Although existing biomarkers such as epidermal growth factor receptor EGFR mutations, ALK rearrangements, and PD-L1 expression have significantly advanced the diagnosis and treatment of non-small cell lung cancer, they still possess certain limitations in predicting patient prognosis and guiding personalized therapy. Therefore, the development of new biomarkers is of considerable importance for the early diagnosis, evaluation of disease prognosis, and decisionmaking regarding treatment for non-small cell lung cancer4. Therefore, it is crucial to investigate new NSCLC biomarkers in order to understand the mechanisms of NSCLC.  \nThe SCG5 gene, also known as Secretogranin V, is situated in band 3 of region 1 on the long arm of human chromosome 15. Spanning approximately 55 kb in size, this gene comprises six exons5. Research suggests that theneuroendocrine protein 7B2, which is encoded by SCG5, functions as a molecular chaperone for the proteogen converting enzyme PC2. This role involves preventing the premature activation of PC2 in the regulatory secretory pathway6,7. Notably, abnormal expression of PC2 has been linked to the proliferation and differentiation of various tumor cells8. Studies on human pheochromocytoma have established a direct correlation between  \n1Department of Thoracic Surgery, Affiliated Hospital 6 of Nantong University, Medical School of Nantong University, Nantong 226001, People’s Republic of China. 2Department of Thoracic Surgery, Affiliated Hospital 6 of Nantong University, Yancheng Third People’s Hospital, Yancheng 224000, People’s","cbCaihpvHMtOcmCc","https://ap.wps.com/l/cbCaihpvHMtOcmCc","pdf",6861247,14,"English","# Introduction\n## Background on lung cancer and need for new biomarkers\n## SCG5 gene features and prior evidence in other tumors\n# Methods\n## Bioinformatics analysis using TCGA and GEO datasets\n## Protein validation by Western blotting and immunofluorescence\n## Immune infiltration analysis and clinical data COX regression\n# Results\n## Pan-cancer upregulation of SCG5\n## Higher SCG5 in NSCLC tumors and survival association\n## SCG5 as an independent prognostic factor\n## Correlation between SCG5 and immune cell subpopulations\n# Discussion\n## Clinical relevance and future research implications","[{\"question\":\"What is the main objective of the study on SCG5 in NSCLC?\",\"answer\":\"To evaluate whether Secretogranin V (SCG5) can serve as a prognostic biomarker for non-small cell lung cancer by linking its expression to clinical outcomes and tumor biology.\"},{\"question\":\"How was SCG5 expression assessed in this research?\",\"answer\":\"The study used bioinformatics analysis of TCGA and GEO pan-cancer datasets, and validated elevated SCG5 levels in NSCLC tissues and cell lines with Western blotting and immunofluorescence.\"},{\"question\":\"What prognostic relationship was found between SCG5 expression and patient survival?\",\"answer\":\"Patients with higher SCG5 expression showed lower overall survival, and univariate and multivariate COX regression supported SCG5 as an independent prognostic factor for NSCLC.\"},{\"question\":\"How does SCG5 relate to the immune microenvironment?\",\"answer\":\"Immune infiltration analysis indicated a significant correlation between SCG5 expression and multiple immune cell subpopulations, suggesting SCG5’s potential role in adverse outcomes.\"}]","The potential of secretogranin V as a prognostic biomarker in non-small cell lung cancer - A scientific study | PDF",1790161204,35,[152,156,160,164],{"page_no":8,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6e0f7a344ed007ab54fb098d903dc5cc.webp",983,1291,{"page_no":14,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/443daca02d243df72061c49b445877d8.webp",982,1290,{"page_no":81,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2f4747f34679c8830cdf2d1c4212017a.webp",981,1289,{"page_no":19,"url":165,"width":166,"height":167},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/31f4f6018698aabb6a93a583eaa4f5ff.webp",980,1287]